these - Université de Franche-Comté
these - Université de Franche-Comté these - Université de Franche-Comté
34 Ainsworth SB, Milligan DW. Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review. Am J Respir Med. 2002;1(6):417-33. 35 Hallman M. Lung surfactant phospholipids in the fœtus, newborn, and in the adult;evidence of abnormality in respiratory failure. Ann Chir Gynaecol Supll. 1982;196:19-23. 36 Robertson B, Halliday HL. Principles of surfactant replacement. Biochim Biophys Acta. 1998 Nov 19;1408(2-3):346-61. 37 Greenough A. Department of Child Health, King's College, London. Replacement surfactant therapy. Prof Care Mother Child. 1997;7(4):99-100. 38 Mugford M, Howard S. Cost effectiveness of surfactant replacement in preterm babies. Pharmacoeconomics. 1993 May;3(5):362-73. 39 Lachmann B. Department of Anesthesiology, Erasmus University, Rotterdam, The Netherlands. Animal studies of surfactant replacement therapy. Dev Pharmacol Ther. 1989;13(2-4):164-72. 40 Awasthi S, Coalson JJ, Yoder BA, Crouch E, King RJ. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Am J Respir Crit Care Med. 2001 Feb;163(2):389-97. 140
41 Gortner L. Natural surfactant for neonatal respiratory distress syndrome in very premature infants: a 1992 update. J Perinat Med. 1992;20(6):409-19. 42 Corbet A. Clinical trials of synthetic surfactant in the respiratory distress syndrome of premature infants. Clin Perinatol. 1993 Dec;20(4):737-60 43 Hallman M, Merritt TA, Bry K. The fate of exogenous surfactant in neonates with respiratory distress syndrome. Clin Pharmacokinet. 1994 Mar;26(3):215-32. 44 Holm BA, Waring AJ. Designer surfactants. The next generation in surfactant replacement. Clin Perinatol. 1993 Dec;20(4):813-29. 45 Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD001079. 46 Wiseman LR, Bryson HM. Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome. Drugs. 1994 Sep;48(3):386-403. 47 Rutkowska M. Comparison of the early response to natural and synthetic surfactant in premature babies with respiratory distress syndrome. Med Wieku Rozwoj. 2000;4(2 Suppl 3):29-42. 141
- Page 111: TROISIEME PARTIE TRAITEMENT DU SYND
- Page 114 and 115: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 116 and 117: Figure 35: mécanisme des lésions
- Page 118 and 119: Mais on peut aussi les séparer en
- Page 120 and 121: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 122 and 123: 2.2. Pharmacologique SDRA : INTERÊ
- Page 124 and 125: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 126 and 127: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 128 and 129: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 130 and 131: SDRA : INTERÊT DU SURFACTANT EXOGE
- Page 132 and 133: 3.3. Conclusion sur l’utilisation
- Page 134 and 135: 112
- Page 136 and 137: 114
- Page 138 and 139: 116
- Page 140 and 141: demi-doses : une moitié dans la br
- Page 142 and 143: 120
- Page 144 and 145: la tête et le corps étant inclin
- Page 146 and 147: 124
- Page 148 and 149: 126
- Page 150 and 151: COLLAPSUS : affaissement d’un org
- Page 152 and 153: MALADIE DES MEMBRANES HYALINES : ca
- Page 154 and 155: TRANSSUDAT : liquide organique d’
- Page 156 and 157: 134
- Page 158 and 159: 8 Rooney SA, Young SL, Mendelson CR
- Page 160 and 161: 22 Post M, Batenburg JJ, van Golde
- Page 164 and 165: 48 Le dictionnaire VIDAL 2005. Pari
- Page 166 and 167: 59 Pfenninger J, Aebi C, Bachmann D
- Page 168 and 169: 70 Long W, Corbet A, Cotton R, Cour
- Page 170 and 171: 84 Günther A, Ruppert C, Schmidt R
- Page 172 and 173: 96 Walmrath D, Gunther A, Ghofrani
- Page 174 and 175: 107 Anzueto A, Baughman RP, Guntupa
- Page 176 and 177: 154
- Page 178 and 179: Protéines.........................
- Page 180 and 181: Surfexo® ou Palmitate de colfocér
- Page 182: 160
41 Gortner L.<br />
Natural surfactant for neonatal respiratory distress syndrome in very premature<br />
infants: a 1992 update.<br />
J Perinat Med. 1992;20(6):409-19.<br />
42 Corbet A.<br />
Clinical trials of synthetic surfactant in the respiratory distress syndrome of premature<br />
infants.<br />
Clin Perinatol. 1993 Dec;20(4):737-60<br />
43 Hallman M, Merritt TA, Bry K.<br />
The fate of exogenous surfactant in neonates with respiratory distress syndrome.<br />
Clin Pharmacokinet. 1994 Mar;26(3):215-32.<br />
44 Holm BA, Waring AJ.<br />
Designer surfactants. The next generation in surfactant replacement.<br />
Clin Perinatol. 1993 Dec;20(4):813-29.<br />
45 Soll RF.<br />
Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm<br />
infants.<br />
Cochrane Database Syst Rev. 2000;(2):CD001079.<br />
46 Wiseman LR, Bryson HM.<br />
Porcine-<strong>de</strong>rived lung surfactant. A review of the therapeutic efficacy and clinical<br />
tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory<br />
distress syndrome.<br />
Drugs. 1994 Sep;48(3):386-403.<br />
47 Rutkowska M.<br />
Comparison of the early response to natural and synthetic surfactant in premature<br />
babies with respiratory distress syndrome.<br />
Med Wieku Rozwoj. 2000;4(2 Suppl 3):29-42.<br />
141
Change language